Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial
March 24, 2021Research and Development COVID-19, Roche, covid-19 treatment
Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …
Pfizer and Myovant’s menstrual blood loss treatment reports 78% effectiveness
March 24, 2021Research and Development Myovant, Pfizer, Phase III trial, fibroids, uterine fibroids
Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine fibroids has shown promising results …
Novo Nordisk obesity treatment successful in clinical trials
March 24, 2021Research and Development Novo Nordisk, obesity
New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …
Guerbet see positive Phase III results for MRI agent
March 24, 2021Research and Development MRI
Medical imaging company, Guerbet, have announced the success of its Phase III study into the safety and efficacy of Gadopiclenol, …
Zealand’s Zegalogue treatment for hypoglycemia approved by FDA
March 23, 2021Manufacturing and Production FDA, Zealand Pharma, Zegalogue
The FDA have approved Zealand Pharma’s Zegalogue therapy for the treatment of severe hypoglycemia in patients with diabetes.
Incyte biliary tract cancer treatment approved in Japan
March 23, 2021Manufacturing and Production EMA, Japan, oncology
The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …
Accord Healthcare launches thalidomide for multiple myeloma treatment
March 23, 2021Manufacturing and Production MHRA, oncology
Accord Healthcare has announced the UK launch of a generic thalidomide, which is used in combination with melphalan and prednisone, …
Roche’s Huntington’s disease treatment disappoints in Phase III trial
March 23, 2021Manufacturing and Production Huntington's, Phase III trial, Roche, huntington's disease, tominersen
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.
Novartis prostate cancer treatment sees positive Phase III results
March 23, 2021Manufacturing and Production Novartis, oncology
Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …
eTheRNA awarded €6.9 million TIGER Grant by European Commission
March 22, 2021Sales and Marketing Cancer, EU
eTheRNA immunotherapies, a clinical-stage company, has been awarded a grant of €6.9 million by the European Commission to develop a …
Daiichi Sankyo begins trial for mRNA COVID-19 vaccine in Japan
March 22, 2021Sales and Marketing COVID-19, Vaccine
Daiichi Sankyo, a global pharmaceutical company that provides services in 20 countries worldwide, has announced the first vaccinations as part …
FDA approves Kiniksa’s recurrent pericardis treatment ARCALYST
March 22, 2021Sales and Marketing FDA
The FDA have approved ARCALYST (rilonacept) for the treatment and risk reduction of recurrent pericardis in adults and children over …
Roche lung cancer treatment reports promising results in Phase III
March 22, 2021Sales and Marketing Roche, oncology
Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …
AstraZeneca COVID-19 vaccine achieves safety and efficacy results in US
March 22, 2021Sales and Marketing
Results from the US trial of AstraZeneca’s COVID-19 vaccine (AZD1222) show it is 79% effective at stopping symptomatic COVID-19 disease …
Pharmafile.com’s top 10 news stories of the week
March 19, 2021Medical Communications COVID, COVID-19, covid 19 news, covid-19 news, news, news roundup, pharma news
In the last week, a number of new developments have made the news; for COVID-19, the Oxford-AstraZeneca vaccine has been …
RDIF & Stelis Biopharma to supply 200 million doses of the Sputnik V vaccine
March 19, 2021Medical Communications COVID-19, Russia, Vaccine
The Russian Direct Investment Fund (RDIF) and Stelis Biopharma have today announced a partnership which aims to produce and supply …
NICE recommends new triple therapy for multiple myeloma patients
March 19, 2021Medical Communications NHS England, NICE, oncology
A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …
AstraZeneca COVID-19 vaccine deemed “safe and effective” by EMA
March 19, 2021Medical Communications AstraZeneca, COVID-19, EMA, Vaccine
AstraZeneca’s COVID-19 vaccine has been cleared for continued use by the EMA following an investigation into the reports of 37 …
AstraZeneca & MSD ovarian cancer drug combination approved by NICE
March 19, 2021Medical Communications AstraZeneca, MSD, NICE, oncology
A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …
Antion launch new technology for cancer and tumour treatments
March 18, 2021Cancer, action, blood cancer, myeloma
Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
